Janssen reports long-term safety data for esketamine in treatment-resistant depression

The Janssen Pharmaceuticals Inc. unit of Johnson & Johnson (NYSE:JNJ) reported data from the Phase III SUSTAIN-2 long-term safety study evaluating intranasal esketamine (formerly JNJ-54135419) plus an oral antidepressant to treat treatment-resistant depression showing there were five treatment-emergent serious adverse events deemed to be related to esketamine. There were 68 total serious treatment-emergent adverse events, including five esketamine-related events. Data were presented at the International College of Neuropsychopharmacology meeting in Vienna.

The primary endpoint of the open-label, international trial was safety...